288 studies found for:    "Breast Neoplasms, Male"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting Finasteride (MK-0906) and Male Breast Cancer - A Register-Based Nested Case-Control Study (MK-0906-162/2003.021)
Condition: Male Breast Cancer
Intervention:
2 Unknown  A Prospective, Randomised, Multi-centre Phase II Study Evaluating the Adjuvant, Neoadjuvant or Palliative Treatmant With Tamoxifen +/- GnRH Analogue Versus Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients
Condition: Male Breast Cancer
Interventions: Drug: Tamoxifen;   Drug: Tamoxifen and GnRH analogue;   Drug: Exemestane and GnRH analogue
3 Completed
Has Results
Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer
Conditions: Breast Cancer;   Breast Neoplasms, Male;   Carcinoma, Ductal
Intervention: Drug: pemetrexed
4 Completed Male Breast Cancer Summa Health System/Akron City Hospital Experience 1995-2007
Condition: Breast Cancer
Intervention:
5 Active, not recruiting Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer
Conditions: Central Nervous System Metastases;   Invasive Ductal Breast Carcinoma;   Invasive Ductal Breast Carcinoma With Predominant Intraductal Component;   Invasive Lobular Breast Carcinoma;   Invasive Lobular Breast Carcinoma With Predominant in Situ Component;   Liver Metastases;   Lobular Breast Carcinoma in Situ;   Lung Metastases;   Male Breast Cancer;   Medullary Ductal Breast Carcinoma With Lymphocytic Infiltrate;   Mucinous Ductal Breast Carcinoma;   Papillary Ductal Breast Carcinoma;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Tubular Ductal Breast Carcinoma;   Tumors Metastatic to Brain
Interventions: Radiation: hyperfractionated radiation therapy;   Other: laboratory biomarker analysis;   Radiation: stereotactic radiosurgery
6 Active, not recruiting Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Biological: HER-2/neu peptide vaccine;   Other: laboratory biomarker analysis
7 Completed Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
Conditions: Adenocarcinoma of the Colon;   Adenocarcinoma of the Gallbladder;   Adenocarcinoma of the Pancreas;   Adenocarcinoma of the Rectum;   Adult Primary Hepatocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Cholangiocarcinoma of the Gallbladder;   Diffuse Adenocarcinoma of the Stomach;   Intestinal Adenocarcinoma of the Stomach;   Male Breast Cancer;   Mixed Adenocarcinoma of the Stomach;   Ovarian Endometrioid Adenocarcinoma;   Paget Disease of the Breast With Intraductal Carcinoma;   Paget Disease of the Breast With Invasive Ductal Carcinoma;   Recurrent Adult Primary Liver Cancer;   Recurrent Breast Cancer;   Recurrent Colon Cancer;   Recurrent Gallbladder Cancer;   Recurrent Gastric Cancer;   Recurrent Malignant Testicular Germ Cell Tumor;   Recurrent Pancreatic Cancer;   Recurrent Rectal Cancer;   Recurrent Salivary Gland Cancer;   Salivary Gland Adenocarcinoma;   Stage II Malignant Testicular Germ Cell Tumor;   Stage II Pancreatic Cancer;   Stage III Colon Cancer;   Stage III Gastric Cancer;   Stage III Malignant Testicular Germ Cell Tumor;   Stage III Pancreatic Cancer;   Stage III Rectal Cancer;   Stage III Salivary Gland Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IV Breast Cancer;   Stage IV Colon Cancer;   Stage IV Gastric Cancer;   Stage IV Pancreatic Cancer;   Stage IV Rectal Cancer;   Stage IV Salivary Gland Cancer;   Thyroid Gland Medullary Carcinoma;   Unresectable Gallbladder Cancer
Interventions: Biological: recombinant fowlpox-CEA(6D)/TRICOM vaccine;   Biological: sargramostim;   Biological: recombinant fowlpox GM-CSF vaccine adjuvant
8 Active, not recruiting Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: cixutumumab;   Drug: temsirolimus;   Other: laboratory biomarker analysis
9 Recruiting Heavy Metal Exposure in Predicting Peripheral Neuropathy in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy
Conditions: Male Breast Cancer;   Neurotoxicity;   Peripheral Neuropathy;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Other: laboratory biomarker analysis;   Other: questionnaire administration
10 Completed Pazopanib in Treating Patients With Recurrent or Metastatic Breast Cancer
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: pazopanib hydrochloride;   Procedure: pharmacological study;   Procedure: laboratory biomarker analysis
11 Completed Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast Cancer
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: trastuzumab;   Drug: gefitinib;   Other: laboratory biomarker analysis
12 Completed Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer
Conditions: Male Breast Cancer;   Nausea and Vomiting;   Stage I Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer
Interventions: Drug: palonosetron hydrochloride;   Drug: cyclophosphamide;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Procedure: quality-of-life assessment;   Procedure: nausea and vomiting therapy;   Procedure: management of therapy complications;   Drug: ondansetron hydrochloride;   Other: survey administration
13 Active, not recruiting Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: HER-2/neu intracellular domain protein;   Procedure: leukapheresis;   Other: laboratory biomarker analysis;   Biological: sargramostim;   Other: immunologic technique;   Biological: synthetic tumor-associated peptide vaccine therapy
14 Recruiting FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast Cancer
Conditions: Male Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer
Interventions: Radiation: fludeoxyglucose F 18;   Device: positron emission tomography;   Device: dynamic contrast-enhanced magnetic resonance imaging;   Other: laboratory biomarker analysis
15 Active, not recruiting Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer
Conditions: Inflammatory Breast Cancer;   Male Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: sunitinib malate;   Drug: paclitaxel;   Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Biological: filgrastim;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis;   Other: flow cytometry
16 Completed Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors
Conditions: Male Breast Cancer;   Recurrent Adenoid Cystic Carcinoma of the Oral Cavity;   Recurrent Basal Cell Carcinoma of the Lip;   Recurrent Breast Cancer;   Recurrent Colon Cancer;   Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Gastric Cancer;   Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Lymphoepithelioma of the Nasopharynx;   Recurrent Lymphoepithelioma of the Oropharynx;   Recurrent Melanoma;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Mucoepidermoid Carcinoma of the Oral Cavity;   Recurrent Ovarian Epithelial Cancer;   Recurrent Prostate Cancer;   Recurrent Renal Cell Cancer;   Recurrent Salivary Gland Cancer;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Stage III Adenoid Cystic Carcinoma of the Oral Cavity;   Stage III Basal Cell Carcinoma of the Lip;   Stage III Colon Cancer;   Stage III Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Stage III Gastric Cancer;   Stage III Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Stage III Lymphoepithelioma of the Nasopharynx;   Stage III Lymphoepithelioma of the Oropharynx;   Stage III Melanoma;   Stage III Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Stage III Mucoepidermoid Carcinoma of the Oral Cavity;   Stage III Ovarian Epithelial Cancer;   Stage III Renal Cell Cancer;   Stage III Salivary Gland Cancer;   Stage III Squamous Cell Carcinoma of the Hypopharynx;   Stage III Squamous Cell Carcinoma of the Larynx;   Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage III Squamous Cell Carcinoma of the Nasopharynx;   Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage III Verrucous Carcinoma of the Larynx;   Stage III Verrucous Carcinoma of the Oral Cavity;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IV Basal Cell Carcinoma of the Lip;   Stage IV Breast Cancer;   Stage IV Colon Cancer;   Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Stage IV Gastric Cancer;   Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Stage IV Lymphoepithelioma of the Nasopharynx;   Stage IV Lymphoepithelioma of the Oropharynx;   Stage IV Melanoma;   Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Stage IV Mucoepidermoid Carcinoma of the Oral Cavity;   Stage IV Ovarian Epithelial Cancer;   Stage IV Prostate Cancer;   Stage IV Renal Cell Cancer;   Stage IV Salivary Gland Cancer;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Squamous Cell Carcinoma of the Larynx;   Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IV Squamous Cell Carcinoma of the Oropharynx;   Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IV Verrucous Carcinoma of the Larynx;   Stage IV Verrucous Carcinoma of the Oral Cavity;   Unspecified Adult Solid Tumor, Protocol Specific;   Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions: Drug: alvespimycin hydrochloride;   Other: laboratory biomarker analysis;   Other: pharmacological study
17 Completed
Has Results
Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer
Conditions: Male Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer
Interventions: Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Biological: bevacizumab;   Drug: paclitaxel;   Biological: filgrastim;   Biological: pegfilgrastim;   Radiation: radiation therapy;   Drug: tamoxifen citrate;   Drug: aromatase inhibition therapy
18 Recruiting Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer
Conditions: HER2-negative Breast Cancer;   Inflammatory Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: Romidepsin;   Drug: Abraxane
19 Unknown  PD 0332991 in Treating Patients With Refractory Solid Tumors
Conditions: Adult Solid Tumor;   Adenocarcinoma of the Colon;   Adenocarcinoma of the Rectum;   Adult Central Nervous System Germ Cell Tumor;   Adult Teratoma;   Benign Teratoma;   Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   Familial Testicular Germ Cell Tumor;   HER2-negative Breast Cancer;   HER2-positive Breast Cancer;   Male Breast Cancer;   Ovarian Immature Teratoma;   Ovarian Mature Teratoma;   Ovarian Monodermal and Highly Specialized Teratoma;   Progesterone Receptor-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Recurrent Colon Cancer;   Recurrent Extragonadal Germ Cell Tumor;   Recurrent Extragonadal Non-seminomatous Germ Cell Tumor;   Recurrent Extragonadal Seminoma;   Recurrent Malignant Testicular Germ Cell Tumor;   Recurrent Melanoma;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Rectal Cancer;   Stage III Extragonadal Non-seminomatous Germ Cell Tumor;   Stage III Extragonadal Seminoma;   Stage III Malignant Testicular Germ Cell Tumor;   Stage III Ovarian Germ Cell Tumor;   Stage IV Breast Cancer;   Stage IV Colon Cancer;   Stage IV Extragonadal Non-seminomatous Germ Cell Tumor;   Stage IV Extragonadal Seminoma;   Stage IV Melanoma;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Rectal Cancer;   Testicular Immature Teratoma;   Testicular Mature Teratoma
Interventions: Drug: PD-0332991;   Other: pharmacological study
20 Completed Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: pegylated liposomal doxorubicin hydrochloride;   Drug: cyclophosphamide;   Biological: trastuzumab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years